Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2019 Publisher: Douglas Pharmaceuticals Ltd, P O Box 45 027, Auckland 0651, New Zealand, Phone: (09) 835 0660
Motetis 25 mg tablet.
| Pharmaceutical Form |
|---|
|
Yellow, round, flat tablet with a score line on one side. |
Each Motetis 25 mg tablets contains 25 mg of tetrabenazine.
Excipient(s) with known effect: Contains lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tetrabenazine |
Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours. |
| List of Excipients |
|---|
|
Motetis tablet contains iron oxide yellow, lactose monohydrate, magnesium stearate, pregelatinised maize starch and purified talc. |
HDPE bottle pack with child-resistant caps, containing 112 tablets.
Douglas Pharmaceuticals Ltd, P O Box 45 027, Auckland 0651, New Zealand, Phone: (09) 835 0660
29 November 2011
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
